ONC Earnings Date: Nov 5, 2026 (Estimated) — BeOne Medicines AG
NASDAQ · Healthcare · Biotechnology
Updated
When is ONC's next earnings date?
BeOne Medicines AG (ONC) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.90 on revenue of $1.75B.
How did ONC do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), BeOne Medicines AG posted EPS of $3.84 versus the $1.63 estimate, a beat of 166.7%. Revenue was $1.71B against a $1.62B estimate. The stock's 1-day post-earnings move was +1.4%.
How much does ONC stock move after earnings?
ONC beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 1.63 | 3.84 | +166.67% | $1.71B | ✅ Beat | +1.40% | +11.23% | +12.00% |
| 2026-05-06 | Q1 2026 | 0.79 | 3.24 | +310.13% | $1.51B | ✅ Beat | +5.32% | +5.91% | -5.90% |
| 2026-02-26 | Q4 2025 | 1.42 | 1.95 | +37.32% | $1.50B | ✅ Beat | -8.48% | -15.11% | -21.37% |
| 2025-11-06 | Q3 2025 | 0.80 | 2.65 | +231.25% | $1.41B | ✅ Beat | +3.41% | +17.45% | +0.47% |
| 2025-08-06 | Q2 2025 | 0.35 | 2.25 | +542.86% | $1.32B | ✅ Beat | -2.83% | -6.23% | +3.74% |
| 2025-02-27 | Q4 2024 | -1.02 | -1.43 | -40.20% | $1.13B | ❌ Miss | +7.48% | +1.24% | +1.39% |
| 2024-08-07 | Q2 2024 | -2.33 | -1.15 | +50.64% | $929.2M | ✅ Beat | +3.16% | +9.27% | +11.83% |
| 2024-05-08 | Q1 2024 | -2.89 | -2.41 | +16.61% | $751.7M | ✅ Beat | +2.42% | +0.13% | -1.84% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $1.71B total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 53.6% | $914.2M | +31.6% | $694.4M | $754.9M | $863.8M | $782.3M |
| CHINA | 29.7% | $506.0M | +16.9% | $432.9M | $439.9M | $407.1M | $472.0M |
| Europe | 12.2% | $208.8M | +37.0% | $152.4M | $166.6M | $173.9M | $194.0M |
| All Other Countries Except China And United States Of America | 4.5% | $76.1M | +113.9% | $35.6M | $51.0M | — | $65.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.